QURE
LIVE

Serial Number

98371742

Owner

uniQure IP B.V.

Attorney

Erica R. Halstead

Filing Date

Jan 23, 2024

Add to watchlist:

No watchlists yet
View on USPTO

QURE Trademark

Serial Number: 98371742

QURE is a trademark filed by uniQure IP B.V. on January 23, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

uniQure IP B.V.

Paasheuvelweg 25
Amsterdam 1105BP , NL

Entity Type: 99

Trademark Details

Filing Date

January 23, 2024

Registration Date

Not Registered

Published for Opposition

June 23, 2026

Goods & Services

Viral systems, gene therapy systems, and nucleic acid delivery systems, all comprised of biological preparations in the nature of viruses for use in cell cultures for non-medical, scientific research purposes; viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors all comprised of biological preparations in the nature of viruses for use in cell cultures for non-medical, scientific research purposes

Medical and scientific research, product development and consultancy in the fields of biotechnology, biology, biopharmaceutical research and development, medical science, chemistry and biochemistry; Providing medical and scientific research information and advice in the fields of biotechnology, biology, biopharmaceutical research and development, medical science, chemistry and biochemistry

Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders using gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation; Providing medical information and advice in the field of medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders using gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation

Viral systems, gene therapy systems, nucleic acid delivery systems, all comprised of biological preparations in the nature of viruses for medical purposes; viral vectors, gene therapy vectors, nucleic acid delivery vectors, all comprised of biological preparations in the nature of viruses for medical purposes; pharmaceutical products for the treatment of diseases; biological preparations for use in medical purposes, namely, in medical and clinical gene therapy, nucleic acid-based therapy; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, gene diagnosis and gene testing; pharmaceutical preparations being prophylaxis products for use in nucleic acid-based therapy and gene therapy

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
May 26, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 5, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 5, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 5, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 17, 2026 GNRN
NON-FINAL ACTION E-MAILED
Apr 17, 2026 GNRT
NON-FINAL ACTION WRITTEN
Apr 17, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 27, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Dec 18, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Dec 18, 2025 GNSL
SUSPENSION LETTER WRITTEN
Dec 18, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 15, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2025 CRFA
ASSIGNED TO LIE
Dec 15, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Dec 2, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 9, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 9, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 9, 2025 CNSI
ASSIGNED TO EXAMINER
Sep 9, 2025 DOCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 8, 2025 RCCK
ASSIGNED TO EXAMINER
Apr 1, 2025 DOCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 5, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 5, 2024 GNSL
SUSPENSION LETTER WRITTEN
Nov 5, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 15, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 15, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 27, 2024 GNRN
NON-FINAL ACTION E-MAILED
Aug 27, 2024 GNRT
NON-FINAL ACTION WRITTEN
Aug 27, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 19, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 24, 2024 NWOS
NEW APPLICATION ENTERED
Jan 23, 2024 NWAP